Travere Therapeutics entered June 2026 with two developments in the space of three days that reshaped its near-term picture. On June 1, the San Diego biopharmaceutical company signed a licensing agreement with Everest Medicines for civorebrutinib, a covalent reversible BTK inhibitor, adding a new immune-targeting mechanism to a pipeline built around rare renal and metabolic conditions. Three days later, the ...
